Welcome to our dedicated page for AVAI BIO SEC filings (Ticker: AVAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVAI BIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVAI BIO's regulatory disclosures and financial reporting.
Avai Bio, Inc. (AVAI) reported for the quarter ended June 30, 2026 with no revenue and a net loss of $552,041, compared with a $487,589 loss a year earlier. Operating expenses were $419,783, and additional other expenses of $132,258 were driven by interest on debt, a discount on a convertible note, and a loss on disposal of a subsidiary.
Total assets were $791,750, versus liabilities of $4,014,316, resulting in a stockholders’ deficit of $3,222,566 and a working capital deficit of $3,860,035. Cash increased to $83,586, supported by $533,299 of net cash from financing activities, including new loans and notes. The company discloses substantial doubt about its ability to continue as a going concern and states its disclosure controls and procedures were not effective. Avai Bio continues to position itself as an AI-focused technology and biotech joint-venture company, adding a Wellness Assessment API and maintaining multiple JV and license agreements while relying on external financing and related-party loans to fund operations.
Avai Bio, Inc., a Nevada-based AI technology and IT consulting company, reported a net loss of $1,749,509 for the year ended March 31, 2026, with no revenue. Operating expenses were $1,480,191 and other expenses, mainly discounts and interest on convertible notes and related-party loans, rose sharply.
At March 31, 2026, the company held $23,145 in cash, had a working capital deficit of $3,298,511, total liabilities of $3,387,851 and total assets of $572,696, resulting in a stockholders’ deficit of $2,815,155 and an accumulated deficit of $5,868,019. Auditors and management highlight substantial doubt about its ability to continue as a going concern.
Operations have been funded through frequent issuances of common and preferred stock, conversions of debt to equity, and multiple promissory and convertible notes, some bearing 22% default interest. The company expects capital to last only through 2026/7 and estimates it must raise about $10,000,000 to fully execute its AI-focused growth plans, while its thinly traded OTC QB penny stock remains highly volatile.
Avai Bio, Inc. filed a Form 12b-25 notifying the SEC that its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 could not be filed on time because additional time is needed to complete preparation and compilation of the company's financial statements and related disclosures. The company states it expects to file the 10-K within the 15-calendar-day extension permitted under Rule 12b-25.
Contact for this notification is Vitalis Racius at the telephone number provided. The filing certifies that other periodic reports required during the preceding 12 months have been filed and that no significant change in results of operations versus the prior fiscal year is anticipated to be reported.
Avai Bio, Inc. entered into a Mutual Termination Agreement with Ainnova Tech Inc. on May 7, 2026, ending their Joint Venture and License Agreement that began in November 2024. The joint venture entity, Ai-Nova Acquisition Corp., will be dissolved and its Nevada corporate filings closed.
Both parties agreed to cancel and release all obligations, rights, and liabilities related to the prior arrangement, with no termination penalties or further financial obligations for either side. Avai Bio and Ainnova plan to pursue their business strategies independently while cooperating in good faith to wind down any remaining joint venture activities.
Avaí Bio, Inc. reported another loss-making quarter with no revenue and a larger deficit. For the three months ended December 31, 2025, the company recorded a net loss of $553,727, bringing the nine‑month loss to $1,494,332.
As of December 31, 2025, Avaí Bio had total assets of $172,912, versus total liabilities of $2,967,398, resulting in a stockholders’ deficit of $2,794,486. Cash and cash equivalents were just $50,402, while accounts payable and various loans and convertible notes made up a heavy current liability load.
The company’s auditors highlight substantial doubt about its ability to continue as a going concern, citing recurring losses and the absence of a stable revenue base. Management plans to rely on additional investment capital while pursuing AI and biotech joint ventures that may require up to tens of millions of dollars in future funding commitments.
AVAI Bio, Inc., formerly Avant Technologies, Inc., reported a corporate name change. On February 3, 2026, the Nevada corporation filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name to Avaí Bio, Inc. The company’s ticker symbol will remain “AVAI.”
Avaí Bio, Inc. (formerly Avant Technologies Inc.) filed its quarterly report for the period ended September 30, 2025. The company reported $0 revenue and a net loss of $453,016 for the quarter. For the six months, net loss was $940,605 as operating expenses focused on G&A, marketing, and initial R&D.
Liquidity remains tight: cash was $91,995 and total assets were $231,372, against total liabilities of $2,532,131, resulting in a stockholders’ deficit of $2,300,759. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Operating cash use for the six months was $611,890, largely offset by $622,832 from financing activities, including related party loans and promissory notes carrying default interest terms.
The company outlined two joint ventures: with Ainnova Tech Inc. (commitment up to $20,000,000 over 12 months) and with Austrianova (up to $1.5 million over 18 months), each at 50/50 ownership. It terminated a prior equity line and withdrew a related S-1, and is pursuing revised financing structures. Common shares outstanding were 137,829,465 at quarter-end and 138,031,533 as of November 14, 2025.
Avant Technologies Inc. (AVAI) entered a Joint Venture and License Agreement with SGAustria Pte. Ltd. to form Insulinova, Inc. Effective November 1, 2025, the parties will co-own Insulinova on a 50%/50% basis and operate it under a limited liability company agreement.
Austrianova intends to contribute its proprietary cell encapsulation intellectual property, know-how, and related resources. AVAI will contribute all resources and capital required for the first eighteen months, not to exceed $1.5 million USD, in exchange for Insulinova common stock, and will use its best efforts to help arrange additional funding at no cost to Austrianova. The full agreement is attached as Exhibit 10.1.
Avant Technologies Inc. entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd. (Austrianova) to form a new company, Klothonova Inc. Avant will provide all resources and capital needed for Klothonova’s formation and operations for the next 18 months, up to $1.5 million, in exchange for common stock.
Austrianova, a biotech company specializing in cell biology and proprietary cell encapsulation technology, will contribute its intellectual property, know-how, and resources. Ownership of Klothonova will be split 50% to Avant and 50% to Austrianova, and it will be governed under a limited liability company agreement. The full Joint Venture and License Agreement is attached as Exhibit 10.1.
Avant Technologies Inc. reported that it has filed an application with FINRA to change its corporate name. The company plans to change its name from Avant Technologies Inc. to Avaí Bio, Inc. to better reflect its current business. The ticker symbol will remain “AVAI” until FINRA declares the corporate action effective and, if applicable, assigns a new trading symbol.